PT  - JOURNAL ARTICLE
AU  - Kapil Agarwal
AU  - Nadia Yousaf
AU  - Daniel Morganstein
TI  - Glucocorticoid use and complications following immune checkpoint inhibitor use in melanoma
AID  - 10.7861/clinmed.2018-0440
DP  - 2020 Mar 01
TA  - Clinical Medicine
PG  - 163--168
VI  - 20
IP  - 2
4099  - http://www.rcpjournals.org/content/20/2/163.short
4100  - http://www.rcpjournals.org/content/20/2/163.full
SO  - Clin Med2020 Mar 01; 20
AB  - Background Immune checkpoint inhibitors have demonstrated benefit in the treatment of cancer, but are associated with toxicities, which often require treatment with glucocorticoids.Aims We aimed to determine the prevalence of glucocorticoid use in patients treated with immune checkpoint inhibitors for melanoma in a single centre.Methods We performed a retrospective review of patients with advanced melanoma treated with an immune checkpoint inhibitor between September 2010 and January 2017. Patients treated with glucocorticoids had a cumulative dose and duration of glucocorticoid treatment calculated. New onset hyperglycaemia was also identified.Results Of 412 patients receiving immune checkpoint therapy, 157 (38%) required glucocorticoids to treat toxicities. The median cumulative glucocorticoid dose was 2,795 mg (prednisolone equivalent) with a median duration of 61 days. Twenty-seven patients receiving glucocorticoids were noted to develop new onset hyperglycaemia.Conclusions Immune-related adverse events frequently occur in patients treated with immune checkpoint inhibitors. Consequently, patients receive prolonged courses of glucocorticoids. Awareness of glucocorticoid-induced side effects is required.